Categories
Change Password!
Reset Password!
A study (Dutch BioDay Registry) investigated the influence of dupilumab therapy on presenteeism, absenteeism, and associated costs in a large multi-centre cohort of 218 adults suffering from atopic dermatitis.
In adults with difficult-to-treat atopic
dermatitis in daily practice, dupilumab therapy remarkably improved work
productivity and declined the associated costs.
A study (Dutch BioDay Registry) investigated the
influence of dupilumab therapy on presenteeism, absenteeism, and associated
costs in a large multi-centre cohort of 218 adults suffering from atopic
dermatitis.
The study recruited atopic dermatitis people who
were given dupilumab therapy. With the aid of Work Productivity and Activity
Impairment questionnaire, estimation of work presenteeism, absenteeism, and
associated costs at the baseline and during the follow-up was done.
At week 52, a considerable drop in total work impairment and median weekly productivity losses was reported when compared to the baseline in dupilumab recipients, as shown in Table 1:
A sustained and rapid decline in work
presenteeism, absenteeism, and related costs were noted in individuals having
atopic dermatitis and managed with dupilumab in daily practice for about 52
weeks.
Acta dermato-venereologica.
Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry
Lieneke F M Ariëns et al.
Comments (0)